- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06671886
Caminho de cuidados clínicos NAFLD (NCCP)
Testando a eficácia do caminho de atendimento clínico NAFLD na atenção primária VA
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatment of NAFLD. This clinical trial will test the benefit of this NCCP intervention against usual care in increasing the rates of NAFLD diagnosis as well as referral to and enrollment in appropriate treatment. The study will also identify barriers and promotors of future NCCP implementation.
Visão geral do estudo
Descrição detalhada
Background: In the United States, non-alcoholic fatty liver disease (NAFLD) affects 25-30% of adults and has become a leading cause of chronic liver disease including cirrhosis and liver cancer. The burden of NAFLD and its complications among patients in the Department of Veterans Affairs (VA) is increasing. Most complications occur among patients with advanced hepatic fibrosis. Treatment (e.g., weight loss) improves patients' outcomes.
Significance: The investigator's data indicate that most VA patients with NAFLD are undiagnosed and untreated. There is an urgent need to address this major gap in care. Most people with NAFLD are seen in primary care settings. The NAFLD Clinical Care Pathway (NCCP) is a multistep, algorithmic process that entails identification of patients at risk through an e-trigger (Step 1), targeted history and lab testing (Step 2), noninvasive testing for hepatic fibrosis using FIB-4 (Step 3), elective additional fibrosis testing with Fibroscan for those with indeterminate FIB-4 (Step 4), and subsequent recommended management. The NCCP has face and content validity based on consensus of multiple stakeholders including VA clinicians, and high efficacy in the investigator's preliminary data. The investigators propose to adapt the multicomponent NCCP intervention for use in VA primary care and prospectively test its effectiveness for identification and severity stratification of patients with NAFLD. The investigator's approach is consistent with VA strategic priorities to implement a more "Veteran-centered" approach that improves access to care.
Innovation & Impact: This is the first study to examine the effectiveness of any NAFLD clinical care pathway in a VA primary care practice. The design is a cluster-randomized controlled trial with randomization at the level of Patient Aligned Care Teams (PACTs) in primary care, and a state-of-the-art technique to diagnose NAFLD and stage the severity of hepatic fibrosis. The investigator's formative and summative evaluation will provide key information about the feasibility, acceptability and determinants of implementation. The NCCP intervention is a paradigm shift in NAFLD care from haphazard and sporadic care into a systematic, equitable, and evidence-based approach.
Specific Aims: Aim 1. Conduct a formative evaluation to assess feasibility and acceptability of the NCCP among patients and providers; adapt the NCCP for prospective testing based on feedback. Aim 2. Examine the effectiveness of the NCCP intervention compared to usual care in improving NAFLD care processes and patient outcomes. Aim 3. Conduct a summative evaluation to identify patient and provider characteristics associated with effectiveness of NCCP and to assess future implementation. The investigator's hypothesis is that NCCP when adapted to Patient Aligned Care Teams (PACTs) in VA primary care considerably increases the identification of patients with NAFLD and those with high-risk NAFLD, and results in an increase in guideline-concordant management.
Methodology: The study will be conducted in primary care settings in a single large VA Medical Center. The investigators will conduct patient interviews and focus groups with PACTs to inform adaption of the NCCP. The investigators will then conduct a cluster-randomized trial of 16 PACTs in primary care to compare the effectiveness of NCCP to usual care in improving NAFLD care, with PACTs as unit of randomization and patients as the unit of analysis. The multicomponent intervention includes an e-trigger to identify patients eligible for NAFLD screening and calculate fibrosis scores, a structured provider education on NAFLD management and treatment recommendations, and coordination by an inter-professional team. The primary outcome will be a composite binary variable consisting of NAFLD diagnosis and risk stratification. Secondary outcomes include referral to a weight loss program, referral of patients with advanced fibrosis to hepatology specialty care, and enrollment among those referred to weight loss and hepatology specialty care. Summative evaluation will inform future implementation.
Next Steps/Implementation: The investigators study will provide information needed to support future projects to implement the NCCP in VA primary care settings. The study will also lay the foundation for a subsequent project to examine the adopted intervention's effect on weight loss and NAFLD biomarkers in patients with high-risk NAFLD.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Hashem B El-Serag, MD MPH
- Número de telefone: (713) 794-8640
- E-mail: Hashem.El-Serag@va.gov
Estude backup de contato
- Nome: Kyler Godwin, PhD MPH BS
- Número de telefone: (713) 440-4672
- E-mail: kyler.godwin@va.gov
Locais de estudo
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-4211
- Recrutamento
- Michael E. DeBakey VA Medical Center, Houston, TX
-
Contato:
- Hashem B El-Serag, MD MPH
- Número de telefone: (713) 794-8640
- E-mail: Hashem.El-Serag@va.gov
-
Contato:
- Kyler Godwin, PhD MPH BS
- Número de telefone: (713) 440-4672
- E-mail: kyler.godwin@va.gov
-
Investigador principal:
- Hashem B. El-Serag, MD MPH
-
Subinvestigador:
- Kyler Godwin, PhD MPH BS
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center
Exclusion Criteria:
-
The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization
-
PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination
-
PACTs meeting the following criteria will be excluded from randomization in Aim 2:
- PACTs who do not treat NAFLD
- PACTs not located at the main hospital
- PACTs with less than 100 visits within 3 months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: E-trigger
The NCCP Intervention is made up of multiple components. The investigators will start by applying the e-trigger and assessing the FIB-4 score, and then will train and educate PACT personnel on managing patients with positive triggers, including making treatment recommendations in collaboration with an inter-professional team. The e-trigger will be generated every three months. |
The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned. |
|
Sem intervenção: Usual care
The control group will receive no additional training or education. PACTs will provide usual care. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
NAFLD Diagnosis and risk stratification
Prazo: Baseline, 6 months
|
The investigators will use chart reviews to extract unstructured data regarding the primary outcome measure: existence of electronic health record (EHR) progress note documenting a new NAFLD diagnosis AND complete risk stratification of NAFLD (i.e., fibrosis). The investigators will use our validated process to guide uniform abstraction and classification. |
Baseline, 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Fibroscan Test
Prazo: Baseline, 6 & 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient had a fibroscan test. |
Baseline, 6 & 12 months
|
|
Referral to hepatology
Prazo: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to a hepatology clinic. |
Baseline, 6 and 12 months
|
|
Hepatology Clinic Visit
Prazo: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was seen in a hepatology clinic. |
Baseline, 6 and 12 months
|
|
NAFLD discussion
Prazo: 6 and 12 months
|
The investigators will extract from the patient chart if the provider documented a discussion about NAFLD with the patient. |
6 and 12 months
|
|
Referral to weight loss services
Prazo: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
|
Enrollment in weight loss services
Prazo: Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hashem B. El-Serag, MD MPH, Michael E. DeBakey VA Medical Center, Houston, TX
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IIR 22-071
- 5I01HX003655-03 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The investigators will not share data at the individual level, only in aggregate. No data will leave the VA.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .